These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1122 related articles for article (PubMed ID: 18038274)

  • 1. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
    Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E
    Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
    Carter CA; Chen C; Brink C; Vincent P; Maxuitenko YY; Gilbert KS; Waud WR; Zhang X
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):183-95. PubMed ID: 16724239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of human non-small cell lung cancer xenografts to cyclophosphamide and cisplatin.
    Mattern J; Wayss K; Volm M
    In Vivo; 1987; 1(1):23-6. PubMed ID: 2856516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma.
    Budak-Alpdogan T; Chen B; Warrier A; Medina DJ; Moore D; Bertino JR
    Clin Cancer Res; 2009 Feb; 15(4):1232-40. PubMed ID: 19174488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
    Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB
    Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
    Hermann TW; Yen WC; Tooker P; Fan B; Roegner K; Negro-Vilar A; Lamph WW; Bissonnette RP
    Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
    Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
    Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experimental evaluation of combination chemotherapy with UFT and cisplatin for lung cancer].
    Uchida J; Satake H; Saito H; Nakano K; Takeda S; Unemi N
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1001-8. PubMed ID: 8210249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
    NĂ©mati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
    Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antitumor activity of combination treatment of BOF-A2 with CDDP against human lung cancers xenografted in nude mice].
    Fujita F; Fujita M; Sakamoto Y; Taguchi T
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):215-21. PubMed ID: 8382036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].
    Gao ZQ; Han BH; Sha HF; Shi ZY; Yang XH; Feng JX
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Apr; 33(4):284-8. PubMed ID: 20646461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic study of trimetrexate in combination with cisplatin.
    Hudes GR; LaCreta F; Walczak J; Tinsley P; Litwin S; Comis RL; O'Dwyer PJ
    Cancer Res; 1991 Jun; 51(12):3080-7. PubMed ID: 1828188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
    Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
    Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
    Singh RP; Mallikarjuna GU; Sharma G; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
    Clin Cancer Res; 2004 Dec; 10(24):8641-7. PubMed ID: 15623648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
    Bible KC; Kaufmann SH
    Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
    Zhong S; Yu D; Wang Y; Qiu S; Wu S; Liu XY
    Acta Oncol; 2010; 49(1):91-9. PubMed ID: 19734998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
    Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
    Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.